$2.09 Billion is the total value of Avoro Capital Advisors LLC's 58 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 72.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IMMU | Buy | IMMUNOMEDICS INC | $247,486,000 | -4.7% | 16,939,461 | +5.4% | 11.82% | -29.8% |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $142,962,000 | +36.8% | 9,505,447 | +30.9% | 6.83% | +0.8% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $138,710,000 | +30.8% | 1,710,995 | +43.8% | 6.62% | -3.7% |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $136,527,000 | +224.8% | 8,078,505 | +53.8% | 6.52% | +139.4% |
| ASND | Buy | ASCENDIS PHARMAsponsored adr | $134,942,000 | +100.4% | 2,063,336 | +22.7% | 6.44% | +47.6% |
| AVXS | Buy | AVEXIS INC | $83,449,000 | +26.5% | 675,262 | +13.3% | 3.98% | -6.8% |
| TGTX | Buy | TG THERAPEUTICS INC | $74,261,000 | +174.9% | 5,229,619 | +58.7% | 3.55% | +102.5% |
| HZNP | Buy | HORIZON PHARMA PLC | $73,253,000 | +13.1% | 5,158,683 | +16.3% | 3.50% | -16.7% |
| ARGX | Buy | ARGENX SEsponsored adr | $69,442,000 | +36.6% | 863,275 | +7.3% | 3.32% | +0.7% |
| CLVS | Buy | CLOVIS ONCOLOGY INC | $61,559,000 | -17.9% | 1,165,884 | +5.7% | 2.94% | -39.5% |
| PBYI | New | PUMA BIOTECHNOLOGY INC | $56,166,000 | – | 825,368 | +100.0% | 2.68% | – |
| MDCO | Buy | MEDICINES CO | $53,884,000 | +52.0% | 1,635,817 | +26.2% | 2.57% | +12.0% |
| ASMB | Buy | ASSEMBLY BIOSCIENCES INC | $53,756,000 | +11.2% | 1,093,934 | +2.4% | 2.57% | -18.1% |
| PCRX | Buy | PACIRA PHARMACEUTICALS INC | $53,424,000 | +37.9% | 1,715,072 | +102.1% | 2.55% | +1.6% |
| ECYT | New | ENDOCYTE INC | $51,769,000 | – | 5,695,200 | +100.0% | 2.47% | – |
| VNDA | Buy | VANDA PHARMACEUTICALS INC | $46,762,000 | +118.4% | 2,775,191 | +97.0% | 2.23% | +60.9% |
| ARMO | New | ARMO BIOSCIENCES INC | $45,173,000 | – | 1,207,500 | +100.0% | 2.16% | – |
| DVAX | New | DYNAVAX TECHNOLOGIES CORP | $32,766,000 | – | 1,650,700 | +100.0% | 1.56% | – |
| DERM | Buy | DERMIRA INC | $27,385,000 | -35.2% | 3,427,378 | +125.5% | 1.31% | -52.3% |
| CBIO | Buy | CATALYST BIOSCIENCES INC | $26,422,000 | +384.3% | 1,024,124 | +156.0% | 1.26% | +256.5% |
| TLGT | Buy | TELIGENT INC | $17,806,000 | -2.9% | 5,299,431 | +5.0% | 0.85% | -28.5% |
| BDSI | Buy | BIODELIVERY SCIENCES INTL | $12,235,000 | +67.9% | 5,437,779 | +120.2% | 0.58% | +23.7% |
| JNCE | New | JOUNCE THERAPEUTICS INC | $11,693,000 | – | 523,174 | +100.0% | 0.56% | – |
| CPRX | Buy | CATALYST PHARMACEUTICALS INC | $11,215,000 | -26.3% | 4,692,343 | +20.6% | 0.54% | -45.6% |
| STML | New | STEMLINE THERAPEUTICS INC | $8,022,000 | – | 524,321 | +100.0% | 0.38% | – |
| ONCS | New | ONCOSEC MEDICAL INC | $7,534,000 | – | 4,007,696 | +100.0% | 0.36% | – |
| KPTI | New | KARYOPHARM THERAPEUTICS INC | $7,524,000 | – | 560,658 | +100.0% | 0.36% | – |
| ACAD | New | ACADIA PHARMACEUTICALS INC | $7,125,000 | – | 317,100 | +100.0% | 0.34% | – |
| VIVE | Buy | VIVEVE MEDICAL INC | $5,612,000 | +9.3% | 1,533,276 | +48.4% | 0.27% | -19.5% |
| TNDM | New | TANDEM DIABETES CARE INC | $3,888,000 | – | 783,910 | +100.0% | 0.19% | – |
| FOLD | Buy | AMICUS THERAPEUTICS INCcall | $3,760,000 | +113.3% | 2,350,100 | +56.7% | 0.18% | +57.9% |
| DOVA | New | DOVA PHARMACEUTICALS INC | $3,390,000 | – | 125,000 | +100.0% | 0.16% | – |
| FENC | Buy | FENNEC PHARMACEUTICALS INC | $3,284,000 | +20.5% | 272,666 | +32.4% | 0.16% | -11.3% |
| SLDB | New | SOLID BIOSCIENCES INC | $2,063,000 | – | 275,000 | +100.0% | 0.10% | – |
| QURE | New | UNIQURE NVshares | $1,592,000 | – | 67,758 | +100.0% | 0.08% | – |
| GBT | New | GLOBAL BLOOD THERAPEUTICS INCcall | $1,444,000 | – | 152,000 | +100.0% | 0.07% | – |
| XBI | New | SPDR SERIES TRUST - S&P BIOTECHput | $998,000 | – | 750,000 | +100.0% | 0.05% | – |
| ACAD | New | ACADIA PHARMACEUTICALS INCcall | $363,000 | – | 500,000 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-06-14 |
| 13F-HR | 2024-05-15 |
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.